Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$11.13 - $15.78 $64,554 - $91,524
5,800 Added 68.35%
14,286 $213,000
Q3 2023

Oct 23, 2023

SELL
$16.15 - $42.35 $240,861 - $631,607
-14,914 Reduced 63.74%
8,486 $137,000
Q4 2022

Feb 14, 2023

BUY
$63.98 - $85.37 $19,194 - $25,611
300 Added 1.3%
23,400 $1.72 Million
Q2 2022

Aug 11, 2022

SELL
$56.6 - $89.9 $526,380 - $836,070
-9,300 Reduced 28.7%
23,100 $1.61 Million
Q1 2022

May 13, 2022

SELL
$60.15 - $84.52 $288,720 - $405,696
-4,800 Reduced 12.9%
32,400 $2.68 Million
Q4 2021

Feb 15, 2022

BUY
$75.08 - $121.99 $2.79 Million - $4.54 Million
37,200 New
37,200 $2.79 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.01B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Fjarde Ap Fonden Portfolio

Follow Fjarde Ap Fonden and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.